Product
GDC-9545
Aliases
Giredestrant, RG6171, RO7197597
Name
Giredestrant
2 clinical trials
1 drug
2 indications
Indication
Breast CancerIndication
Healthy Control ParticipantsDrug
GDC-9545Clinical trial
A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase I, Single Center, Open-Label, Partially Randomized, Two Part Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute Bioavailability of Oral Capsule Formulations of GDC-9545 F12 and F18 and the Relative Bioavailability of F18 Compared to F12 (Part 2) in Healthy Female Subjects of Non-Childbearing PotentialStatus: Completed, Estimated PCD: 2021-04-12